ARS Pharmaceuticals (NASDAQ:SPRY – Get Free Report) and Cronos Group (NASDAQ:CRON – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, profitability, analyst recommendations, dividends and risk.
Profitability
This table compares ARS Pharmaceuticals and Cronos Group’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| ARS Pharmaceuticals | -203.25% | -100.29% | -51.09% |
| Cronos Group | -6.44% | -1.12% | -1.07% |
Earnings & Valuation
This table compares ARS Pharmaceuticals and Cronos Group”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| ARS Pharmaceuticals | $84.28 million | 9.56 | -$171.30 million | ($1.75) | -4.63 |
| Cronos Group | $146.59 million | 6.51 | -$9.45 million | ($0.01) | -251.00 |
Cronos Group has higher revenue and earnings than ARS Pharmaceuticals. Cronos Group is trading at a lower price-to-earnings ratio than ARS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
68.2% of ARS Pharmaceuticals shares are held by institutional investors. Comparatively, 8.7% of Cronos Group shares are held by institutional investors. 33.5% of ARS Pharmaceuticals shares are held by company insiders. Comparatively, 7.3% of Cronos Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Risk & Volatility
ARS Pharmaceuticals has a beta of 0.86, suggesting that its stock price is 14% less volatile than the S&P 500. Comparatively, Cronos Group has a beta of 0.78, suggesting that its stock price is 22% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent recommendations and price targets for ARS Pharmaceuticals and Cronos Group, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ARS Pharmaceuticals | 1 | 1 | 2 | 0 | 2.25 |
| Cronos Group | 1 | 2 | 2 | 0 | 2.20 |
ARS Pharmaceuticals presently has a consensus target price of $29.33, suggesting a potential upside of 261.69%. Cronos Group has a consensus target price of $2.30, suggesting a potential downside of 8.37%. Given ARS Pharmaceuticals’ stronger consensus rating and higher probable upside, equities analysts clearly believe ARS Pharmaceuticals is more favorable than Cronos Group.
Summary
ARS Pharmaceuticals beats Cronos Group on 7 of the 13 factors compared between the two stocks.
About ARS Pharmaceuticals
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.
About Cronos Group
Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.
Receive News & Ratings for ARS Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARS Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
